Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre J-P
Service de Gastroentérologie et Nutrition, Hôpital Saint-Antoine, 184 rue du Faubourg St-Antoine, 75571 Paris cedex 12, France.
Gut. 2005 Feb;54(2):237-41. doi: 10.1136/gut.2004.045294.
BACKGROUND/AIM: Immunosuppressants are now used much earlier in the course of Crohn's disease; however their effect on the natural history of the disease, especially on the need for surgery, is not known. The aim of this study was to assess the evolution of the need for surgery in Crohn's disease during the last 25 years.
The medical charts of 2573 patients were reviewed retrospectively. The use of immunosuppressants (azathioprine or methotrexate), the need for intestinal resection, and the occurrence of intestinal complications were assessed using Kaplan-Meier analysis in five consecutive cohorts of patients defined by the date of diagnosis of Crohn's disease (1978-82; 1983-87; 1988-92; 1993-97; 1998-2002).
In 565 patients seen in the authors' unit within the first three months after diagnosis, characteristics of Crohn's disease at diagnosis did not differ from one cohort to another. The five year cumulative probability to receive immunosuppressants increased from 0 in the 1978-82 cohort to 0.13, 0.25, 0.25, and 0.56 in the 1983-87, 1988-92, 1993-97, and 1998-2002 cohorts, respectively (p<0.001). Concomitantly, the cumulative risk of intestinal resection remained unchanged (from 0.35 to 0.34 at five years; p=0.81). The cumulative risk of developing a stricturing or a penetrating intestinal complication remained also unchanged. Similar results were obtained in the 2008 patients seen during the same period who were referred to us more than three months after diagnosis.
Although immunosuppressants have been used more frequently over the last 25 years, there was no significant decrease of the need for surgery, or of intestinal complications of Crohn's disease.
背景/目的:免疫抑制剂目前在克罗恩病病程中使用得更早;然而,其对疾病自然史的影响,尤其是对手术需求的影响尚不清楚。本研究的目的是评估过去25年中克罗恩病手术需求的演变情况。
回顾性分析2573例患者的病历。在由克罗恩病诊断日期定义的五个连续队列患者(1978 - 82年;1983 - 87年;1988 - 92年;1993 - 97年;1998 - 2002年)中,使用Kaplan - Meier分析评估免疫抑制剂(硫唑嘌呤或甲氨蝶呤)的使用情况、肠道切除需求以及肠道并发症的发生情况。
在诊断后前三个月内作者所在科室诊治的565例患者中,各队列克罗恩病的诊断特征无差异。接受免疫抑制剂的五年累积概率从1978 - 82年队列的0增加到1983 - 87年、1988 - 92年、1993 - 97年和1998 - 2002年队列中的0.13、0.25、0.25和0.56(p<0.001)。同时,肠道切除的累积风险保持不变(五年时从0.35到0.34;p = 0.81)。发生狭窄或穿透性肠道并发症的累积风险也保持不变。在同期诊断三个月后转诊至我们科室的2008例患者中也获得了类似结果。
尽管在过去25年中免疫抑制剂使用得更频繁,但克罗恩病的手术需求或肠道并发症并无显著减少。